世界の医療・医薬品産業レポート

TOP  >  疾患別治験・パイプラインレポート  >  遺伝子  >  多発性嚢胞腎 - パイプラインレビュー 2016年上半期

多発性嚢胞腎 - パイプラインレビュー 2016年上半期
Polycystic Kidney Disease - Pipeline Review, H1 2016

レポートタイトル 多発性嚢胞腎 - パイプラインレビュー 2016年上半期
出版社名 Global Markets Direct
発刊日 2016-04-30
体裁 PDF / 88 ページ
シングルユーザ価格 US$ 2,000
レポート分類 疾患別治験・パイプラインレポート
地域 グローバル
領域 遺伝子
疾患名 多発性嚢胞腎
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記疾患の治療薬開発についての包括的情報、さまざまな開発ステージでの比較分析、薬剤ターゲット、作用機序(MoA)、投与方法(RoA)、分子タイプ別の薬剤評価、および最新情報、ニュースやプレスリリースなどを提供します。
また、上記疾患における治療薬開発に関わる主要企業概要、開発後期および中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Polycystic Kidney Disease Overview 9
Therapeutics Development 10
Pipeline Products for Polycystic Kidney Disease - Overview 10
Pipeline Products for Polycystic Kidney Disease - Comparative Analysis 11
Polycystic Kidney Disease - Therapeutics under Development by Companies 12
Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 13
Polycystic Kidney Disease - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Polycystic Kidney Disease - Products under Development by Companies 17
Polycystic Kidney Disease - Products under Investigation by Universities/Institutes 18
Polycystic Kidney Disease - Companies Involved in Therapeutics Development 19
3SBio Inc. 19
Angion Biomedica Corp. 20
DiscoveryBiomed, Inc. 21
Endocyte, Inc. 22
IC-MedTech, Inc. 23
Ipsen S.A. 24
Kadmon Corporation, LLC 25
Metabolic Solutions Development Company, LLC 26
NovaTarg Therapeutics, Inc 27
Otsuka Holdings Co., Ltd. 28
Synta Pharmaceuticals Corp. 29
Polycystic Kidney Disease - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(ascorbic acid + menadione) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ANG-3070 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CIM-2 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DBM-43H11 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DJ-5 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Drugs for Polycystic Kidney Disease - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
EC-0371 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
JP-153 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
lanreotide acetate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MSDC-0160 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MSDC-0602 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
oxypurinol - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pyrimethamine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
STA-2842 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
tesevatinib tosylate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
tolvaptan - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Polycystic Kidney Disease - Recent Pipeline Updates 67
Polycystic Kidney Disease - Dormant Projects 77
Polycystic Kidney Disease - Discontinued Products 78
Polycystic Kidney Disease - Product Development Milestones 79
Featured News & Press Releases 79
Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease 79
Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015 80
May 28, 2015: Otsuka’s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease 80
Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease 81
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease 82
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease 83
Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide 84
Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease 85
Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease 86
May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88

List of Tables
Number of Products under Development for Polycystic Kidney Disease, H1 2016 10
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Polycystic Kidney Disease - Pipeline by 3SBio Inc., H1 2016 19
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp., H1 2016 20
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed, Inc., H1 2016 21
Polycystic Kidney Disease - Pipeline by Endocyte, Inc., H1 2016 22
Polycystic Kidney Disease - Pipeline by IC-MedTech, Inc., H1 2016 23
Polycystic Kidney Disease - Pipeline by Ipsen S.A., H1 2016 24
Polycystic Kidney Disease - Pipeline by Kadmon Corporation, LLC, H1 2016 25
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company, LLC, H1 2016 26
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 27
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 28
Polycystic Kidney Disease - Pipeline by Synta Pharmaceuticals Corp., H1 2016 29
Assessment by Monotherapy Products, H1 2016 30
Assessment by Combination Products, H1 2016 31
Number of Products by Stage and Target, H1 2016 33
Number of Products by Stage and Mechanism of Action, H1 2016 35
Number of Products by Stage and Route of Administration, H1 2016 37
Number of Products by Stage and Molecule Type, H1 2016 39
Polycystic Kidney Disease Therapeutics - Recent Pipeline Updates, H1 2016 67
Polycystic Kidney Disease - Dormant Projects, H1 2016 77
Polycystic Kidney Disease - Discontinued Products, H1 2016 78

List of Figures
Number of Products under Development for Polycystic Kidney Disease, H1 2016 10
Number of Products under Development for Polycystic Kidney Disease - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 30
Number of Products by Top 10 Targets, H1 2016 32
Number of Products by Stage and Top 10 Targets, H1 2016 32
Number of Products by Top 10 Mechanism of Actions, H1 2016 34
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 34
Number of Products by Routes of Administration, H1 2016 36
Number of Products by Stage and Routes of Administration, H1 2016 36
Number of Products by Molecule Types, H1 2016 38
Number of Products by Stage and Molecule Types, H1 2016 38
Loading....